Natera Valuation Multiples

Natera Overview

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Founded

2007

HQ

Employees

4.4K

Website

natera.com

Sectors

Diagnostics & GenomicsMedical Imaging & DiagnosticsBioTechDeepTechHealthTech

Financials (LTM)

Revenue: $2B

EBITDA: ($260M)

EV

$29B

Valuation Multiples

Multiples.vc

Start free trial

Natera Financials

Natera reported last 12-month revenue of $2B and negative EBITDA of ($260M).

In the same LTM period, Natera generated $2B in gross profit, ($260M) in EBITDA losses, and had net loss of ($219M).

Natera P&L

In the most recent fiscal year, Natera reported revenue of $2B and EBITDA of ($221M).

Natera expects next 12-month revenue of XXX and NTM EBITDA of XXX

Natera Stock Performance

Natera has current market cap of $30B, and enterprise value of $29B.

Natera's stock price is $208.40.

Natera Valuation Multiples

Natera trades at 11.9x EV/Revenue multiple, and (110.2x) EV/EBITDA.

Natera Financial Valuation Multiples

As of April 18, 2026, Natera has market cap of $30B and EV of $29B.

Equity research analysts estimate Natera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Natera has a P/E ratio of (134.7x).

Natera Margins & Growth Rates

Natera's revenue in the last 12 month grew by 17%.

Natera's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

Natera's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Natera's rule of X is 30% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Natera Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Medical Imaging & Diagnostics comps.

Natera M&A Activity

Natera acquired XXX companies to date.

Last acquisition by Natera was on XXXXXXXX, XXXXX. Natera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Natera Investment Activity

Natera invested in XXX companies to date.

Natera made its latest investment on XXXXXXXX, XXXXX. Natera invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).